drugset
drugset / Trial / NCT02824874

CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)

NCT02824874 ↗

Phase 1 Completed 20 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.

Timeline

Start
2016-04
Primary completion
2016-04
Completion
2016-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.5 mg —
Subject Sitagliptin Small molecule 100 mg —

Indications

type 2 diabetes mellitus